A new test to find antiviral compounds targeting SARS-CoV-2 RNA
Official title: A biophysical assay targeting SARS CoV-2 RNA
Funded at Nubad, LLC · NIH-10653818 · Data updated 2026-11-12
This study is looking for new ways to find and target important parts of the SARS-CoV-2 virus's RNA to help create better treatments for COVID-19, which could lead to more effective antiviral medicines for patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nubad, LLC NIH-funded |
| Lab location | 1 site (Greer, United States) |
| Project start | June 27, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $298,689 |
| NIH project number | 5R43AI167095-02 |
| Project ID | NIH-10653818 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals affected by COVID-19 or those at high risk of severe illness from the virus.
✕Less likely to help
Patients who are not currently affected by COVID-19 or who have already recovered may not receive direct benefits from this research.
What this research studies
This research focuses on developing a novel biophysical assay to identify specific RNA structures in the SARS-CoV-2 virus. By using this assay, researchers aim to discover new antiviral compounds that can effectively target these RNA elements, which are crucial for the virus's replication. The approach involves screening for ligands that bind to these RNA structures, potentially leading to the development of new antiviral therapies. Patients may benefit from advancements in treatment options for COVID-19 as a result of this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antiviral medications specifically targeting SARS-CoV-2, improving treatment options for COVID-19.
How similar studies have gone: Other research has shown promise in targeting viral RNA structures for antiviral drug development, indicating that this approach could be effective.
Where this research is happening
-
Nubad, LLC
Greer, United States Active
Researchers
- Principal investigator: Story, Sandra Paige — Nubad, LLC
- Study coordinator: Story, Sandra Paige
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.